News blog

Initiative gets $1.3 million to verify findings of 50 high-profile cancer papers

One of the major concerns in biomedical research today is that many basic findings cannot be easily replicated by other labs. Might the literature be stuffed with flukes and unrepeatable results, not sufficiently checked out before publication, and rarely repeated by other labs? Such doubts have increased in the past year, especially after scientists at Amgen and Bayer reported that they had been unable to reproduce the vast majority of ‘landmark’ papers describing promising approaches to treat disease. 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.